Formations of, Acquisitions by, and Mergers of Bank Holding Companies, 31955 [E9-15776]
Download as PDF
<![CDATA[
Federal Register / Vol. 74, No. 127 / Monday, July 6, 2009 / Notices
the voting shares of Haven Savings
Bank, Hoboken, New Jersey.
Board of Governors of the Federal Reserve
System, July 1, 2009.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E9–15932 Filed 7–2–09; 8:45 am]
BILLING CODE 6210–01–S
FEDERAL RESERVE SYSTEM
mstockstill on PROD1PC66 with NOTICES
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR Part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The applications also will be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Additional information on all bank
holding companies may be obtained
from the National Information Center
Web site at www.ffiec.gov/nic/.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than July 30, 2009.
A. Federal Reserve Bank of
Richmond (A. Linwood Gill, III, Vice
President) 701 East Byrd Street,
Richmond, Virginia 23261–4528:
1. Eastern Virginia Bankshares, Inc.,
Tappahannock, Virginia; to acquire 100
percent of the voting shares of First
Capital Bancorp, Inc., and thereby
indirectly acquire voting shares of First
Capital Bank, both of Glen Allen,
Virginia.
B. Federal Reserve Bank of Dallas (E.
Ann Worthy, Vice President) 2200
VerDate Nov<24>2008
17:12 Jul 02, 2009
Jkt 217001
North Pearl Street, Dallas, Texas 75201–
2272:
1. A.N.B. Holding Company, Ltd.,
Terrell, Texas; to aquire additional
voting shares, for a total of 35 percent,
of The ANB Corporation, and thereby
indirectly acquire additional voting
shares of The American National Bank,
both of Terrell, Texas; Lakeside
Bancshares, Inc., and Lakeside National
Bank, both of Rockwall, Texas.
Board of Governors of the Federal Reserve
System, June 30, 2009.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E9–15776 Filed 7–2–09; 8:45 am]
BILLING CODE 6210–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Scientific Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
SUMMARY: Notice is hereby given that
the Office of Research Integrity (ORI)
and the Assistant Secretary for Health
have taken final action in the following
case:
Judith M. Thomas, PhD, University of
Alabama at Birmingham: Based on a
finding of scientific misconduct made
by the University of Alabama at
Birmingham (UAB) on January 24, 2008,
a report of the UAB Investigation
Committee, dated November 21, 2007,
and additional analysis conducted by
ORI during its oversight review, the U.S.
Public Health Service (PHS) found that
Dr. Judith M. Thomas, former Professor
of Surgery, UAB, engaged in scientific
misconduct in research supported by
National Institute of Allergy and
Infectious Diseases (NIAID), National
Institutes of Health (NIH), grants R01
AI22293, R01 AI39793, and U19
AI056542, National Institute of Diabetes
and Digestive and Kidney Diseases
(NIDDK), NIH, grant U19 DK57958, and
NIH/Novartis Cooperative Research and
Development Agreement 96–MH–01/
NIHITC–0697.
The objective of the research was to
test the effectiveness of different agents,
such as Immunotoxin FN18–CRM9 or
15-deoxyspergualin (15-DSG),
administered around the time of renal
transplantation in non-human primates,
in preventing rejection of the
transplanted kidney. To determine
whether or not the transplanted kidney
was functioning (able to sustain life)
after the immunomodulating therapy,
the animals were to have both of their
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
31955
native kidneys removed at or shortly
after the time of transplant, so that their
survival would depend solely on the
viability of the transplanted kidney. It
was postulated that the use of
immunomodulating agents would
increase tolerance of the host animal to
the grafted kidney and thus eliminate
the necessity for chronic administration
of immunosuppressive medications
commonly required to prevent rejection
in renal transplant recipients. Failure to
remove both native kidneys would
render it impossible to assess the
effectiveness of the immunomodulating
treatment, and could give totally
misleading results, suggesting that the
treatment worked while in fact survival
was due entirely to the remaining native
kidney.
PHS found that Respondent engaged
in scientific misconduct by falsifying
reports of research results in NIHsupported experiments with non-human
primate (NHP) renal allograft recipients
in 15 publications and in progress
reports in two NIH research grant
applications. Specifically, PHS found
that:
1. Respondent falsely reported in 15
publications that NHP renal allograft
recipients had received bilateral
nephrectomies of their native kidneys,
while in fact many of the animals
retained an intrinsic kidney.
Specifically:
A. Respondent falsely reported in
eight publications 1 that at least 32
specific NHPs in a renal
allotransplantation study had received
bilateral nephrectomies, while in fact an
intrinsic kidney was left in place in
each animal, and generally, in seven
additional publications,2 Respondent
falsely reported that all long term
surviving NHP renal allograft recipients
had received bilateral nephrectomies of
their native kidneys. The publications
referenced are listed separately in the
endnotes.
2. In seven publications,3 Respondent
falsely reported immunomodulating
treatments given to NHP renal allograft
recipients by not reporting the
administration of donor bone marrow to
seven recipients and not reporting
administration of cyclosporine A to four
recipients. She also falsely reported (by
overstating by 15%) dosages of the
immunomodulating agents that were
given and/or duration by overstating the
exceptionalbriefer duration of
immunomodulating treatment given to
four recipients and cited in at least eight
publications.4
3. In progress reports for NIH research
awards R01 AI39793 and U19 DK57958,
Respondent falsely claimed that long
term surviving (LTS) NHP renal
E:\FR\FM\06JYN1.SGM
06JYN1
]]>Agencies
[Federal Register Volume 74, Number 127 (Monday, July 6, 2009)]
[Notices]
[Page 31955]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-15776]
-----------------------------------------------------------------------
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and Mergers of Bank Holding
Companies
The companies listed in this notice have applied to the Board for
approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C.
1841 et seq.) (BHC Act), Regulation Y (12 CFR Part 225), and all other
applicable statutes and regulations to become a bank holding company
and/or to acquire the assets or the ownership of, control of, or the
power to vote shares of a bank or bank holding company and all of the
banks and nonbanking companies owned by the bank holding company,
including the companies listed below.
The applications listed below, as well as other related filings
required by the Board, are available for immediate inspection at the
Federal Reserve Bank indicated. The applications also will be available
for inspection at the offices of the Board of Governors. Interested
persons may express their views in writing on the standards enumerated
in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the
acquisition of a nonbanking company, the review also includes whether
the acquisition of the nonbanking company complies with the standards
in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted,
nonbanking activities will be conducted throughout the United States.
Additional information on all bank holding companies may be obtained
from the National Information Center Web site at www.ffiec.gov/nic/.
Unless otherwise noted, comments regarding each of these
applications must be received at the Reserve Bank indicated or the
offices of the Board of Governors not later than July 30, 2009.
A. Federal Reserve Bank of Richmond (A. Linwood Gill, III, Vice
President) 701 East Byrd Street, Richmond, Virginia 23261-4528:
1. Eastern Virginia Bankshares, Inc., Tappahannock, Virginia; to
acquire 100 percent of the voting shares of First Capital Bancorp,
Inc., and thereby indirectly acquire voting shares of First Capital
Bank, both of Glen Allen, Virginia.
B. Federal Reserve Bank of Dallas (E. Ann Worthy, Vice President)
2200 North Pearl Street, Dallas, Texas 75201-2272:
1. A.N.B. Holding Company, Ltd., Terrell, Texas; to aquire
additional voting shares, for a total of 35 percent, of The ANB
Corporation, and thereby indirectly acquire additional voting shares of
The American National Bank, both of Terrell, Texas; Lakeside
Bancshares, Inc., and Lakeside National Bank, both of Rockwall, Texas.
Board of Governors of the Federal Reserve System, June 30, 2009.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E9-15776 Filed 7-2-09; 8:45 am]
BILLING CODE 6210-01-S
